Drugs /

targeted therapy agent

Back to Drugs List

Overview

NCI Definition [1]:
Any agent that specifically targets or interferes with the synthesis or function of a molecule that is expressed specifically in or on cells of the tumor and/or the tumor microenvironment (TME), such as immune cells or surrounding blood vessels. The targeted molecule is usually overexpressed or mutated in tumors but minimally or not expressed by normal, healthy tissues; additionally, expression is typically associated with tumor cell proliferation, progression and/or survival. By blocking the function or expression of the tumor-associated target, the targeted therapy agent may exert potential antineoplastic and/or immunomodulatory activities.

Clinical Trials

View Clinical Trials for targeted therapy agent

Targeted therapy agent has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating targeted therapy agent, 2 are phase 2 (2 open) and 1 is no phase specified (1 open).

BRCA1 Loss, BRCA1 Mutation, and BRCA2 Loss are the most frequent biomarker inclusion criteria for targeted therapy agent clinical trials.

Malignant solid tumor, breast carcinoma, and hematopoietic and lymphoid malignancy are the most common diseases being investigated in targeted therapy agent clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Targeted Therapy Agent
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating targeted therapy agent and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
targeted therapeutic agent, targeted agent, molecularly targeted therapy agent, anti-tumor targeted therapy agent
NCIT ID [1]:
C163758

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.